{"preliminary_commentary":{"by_channel":{"youtube":5,"podcast":4,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06764875\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["rilvegostomig","trastuzumab deruxtecan"]],"indication":"first-line HER2-positive gastric or gastroesophageal junction cancer","name":"ARTEMIDE-Gastric01","nct_id":"NCT06764875","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=artemide-gastric01-nct06764875. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"T-DXd + Rilvegostomig + Fluoropyrimidine (Capecitabine OR 5-FU)","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Pembrolizumab + Trastuzumab + FP (5-FU plus cisplatin) or CAPOX (capecitabine plus oxaliplatin)","label":"Arm B","type":"ACTIVE_COMPARATOR"},{"description":"Rilvegostomig + Trastuzumab + FP (5-FU plus cisplatin) or CAPOX (capecitabine plus oxaliplatin)","label":"Arm C","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-12-09","type":"ESTIMATED"},"conditions":["HER2-positive Gastric Cancer","Gastroesophageal Junction Adenocarcinoma"],"enrollment":{"count":840,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Rilvegostomig","otherNames":["AZD2936"],"type":"DRUG"},{"name":"Trastuzumab deruxtecan","otherNames":["T-DXd, DS-8201"],"type":"DRUG"},{"name":"Trastuzumab","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"5-fluorouracil","otherNames":["5-FU"],"type":"DRUG"},{"name":"Capecitabine","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Oxaliplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-16","lead_sponsor":"AstraZeneca","official_title":"A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-04-27","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS)","timeFrame":"Up to approximately 6 years"},{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 6 years"}],"references":[],"start_date":{"date":"2025-03-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","url":"https://clinicaltrials.gov/study/NCT06764875"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/artemide-gastric01-nct06764875"}